Eterna Therapeutics Inc (ERNA NASDAQ) stock market data APIs
$0.6807
0.13(19.1%)
as of February 5, 2026
Try our APIs with
free plan!
Eterna Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Prev. Close
0.6807
Open
0.8069
High
0.8405
Low
0.6734
52 wk Range
0.67-5.55
Market Cap
5 340 K
P/E Ratio
0.0148
Shares Outstanding
7 854 K
Revenue
1 000
EPS
-0.15
Beta
6.737
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Eterna Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eterna Therapeutics Inc data using free add-ons & libraries
Get Eterna Therapeutics Inc Fundamental Data
Eterna Therapeutics Inc Fundamental data includes:
- Net Revenue: 1 000
- EBITDA: -9 851 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eterna Therapeutics Inc News
New
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the t...
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune dise...
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune dise...
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune dise...
Get Eterna Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
